Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Genome editing to 're-write' wrongs

Nature Reviews Drug Discovery volume 17, pages 689–690 (2018)Cite this article

Subjects

The NIH has launched the Somatic Cell Genome Editing (SCGE) programme to accelerate the development of safer and more effective genome-editing therapeutics.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014).

    Article  CAS  Google Scholar 

  2. Kaiser, J. A human has been injected with gene-editing tools to cure his disabling disease. Here's what you need to know. Science http://www.sciencemag.org/news/2017/2011/human-has-been-injected-gene-editing-tools-cure-his-disabling-disease-here-s-what-you (2017).

  3. Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 168, 20–36 (2017).

    Article  CAS  Google Scholar 

  4. Cyranoski, D. CRISPR gene-editing tested in a person for the first time. Nature 539, 479 (2016).

    Article  CAS  Google Scholar 

  5. Freedman, L. P., Cockburn, I. M. & Simcoe, T. S. The economics of reproducibility in preclinical research. PLOS Biol. 13, e1002165 (2015).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Program Coordination, Office of Strategic Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, Bethesda, MD, USA

    Mary Ellen Perry & Elizabeth Wilder

  2. National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Bethesda, MD, USA

    Kayla M. Valdes, Christopher P. Austin & Philip J. Brooks

Authors
  1. Mary Ellen Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kayla M. Valdes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth Wilder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher P. Austin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philip J. Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip J. Brooks.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

RELATED LINKS

ClinicalTrials.gov

DARPA Safe Genes programme

FDA OTAT

NIH Common Fund Somatic Cell Genome Editing programme

NIH: Rigor and Reproducibility

NIST Gene Editing Consortium

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perry, M., Valdes, K., Wilder, E. et al. Genome editing to 're-write' wrongs. Nat Rev Drug Discov 17, 689–690 (2018). https://doi.org/10.1038/nrd.2018.91

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.91

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research